VentriPoint Diagnostics (VPT) investor relations material

Opening remarks and agenda

• CEO opened with a reminder about forward-looking statements and outlined a shift in strategic focus from product development to commercial adoption and market expansion.

Strategic initiatives and plans

• Focus on moving VMS+ from research to routine clinical use, starting with congenital heart defect centers and expanding to other cardiac indications.

• CRM implementation has evolved to automate customer outreach, resulting in high engagement rates and new appointments.

• Partnerships in Europe, UK, and China are advancing, with Angiopro deepening involvement and Lishman Global nearing regulatory submission in China.

• Collaboration with Providence Health and First Nations aims to expand access and establish a hub-and-spoke model for remote communities.

• Ongoing integration with ASCEND Cardiovascular and joint sales outreach, especially targeting pediatric sites.

• Exploring opportunities in India and Brazil, with early-stage partnerships and NDAs signed.

• Efforts to engage with major valve manufacturers for bundled offerings and cross-selling opportunities.

Financial performance review

• Organization remains lean, with a focus on disciplined financial management and de-risking technology.

• Revenues expected to begin accruing in Q2 2026 and build strongly throughout the year.

• Additional capital will be required to support growth and team expansion.